[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercalciuric-hypercalcemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercalciuric-hypercalcemia":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100308878","phase-2-rifampin-in-cyp24a1-related-hypercalcemia-and-hypercalciuria-100308878",false,"NCT03301038","Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria","Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene","RICHH","Inclusion Criteria:\n\n* Males or females age 6 months to 65 years.\n* at least one mutations of CYP24A1\n* Serum and\u002For urinary calcium above the normal reference range for age\n* Serum PTH concentration \\\u003C20 pg\u002Fml\n* Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.\n\nExclusion Criteria:\n\n* Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n* Allergy to rifampin or related medications\n* Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By \"drug-drug\" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.\n* Pregnancy or breastfeeding\n* Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:\n* Aspartate Aminotransferase (AST\u002FSGOT) \\> 2.0 times the upper limit of normal Alanine aminotransferase (ALT\u002FSGPT) \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal Creatinine \\> 2.0 times the upper limit of normal","ALL","6 Months","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and\u002For hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.",[28,29,30,31,32,33],"Idiopathic Infantile Hypercalcaemia - Severe Form","Genetic Disease","Hypercalcemia, Idiopathic, of Infancy","Hypercalciuric Hypercalcemia","Idiopathic Infantile Hypercalcemia - Mild Form","Hypercalciuria",[35,36,37,38],"hypercalcemia","nephrocalcinosis","CYP24A1","hypercalciuria","RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":43},"2018-07-25",{"date":47,"type":22},"2030-12",{"name":49,"class":50},"Children's Hospital of Philadelphia","OTHER"]